Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma

Next Previous
X
Search
Trial Profile

An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RO 7293583 (Primary) ; RO 7293583 (Primary) ; Adalimumab; Obinutuzumab; Tocilizumab
  • Indications Malignant melanoma; Skin cancer; Uveal neoplasms
  • Focus Adverse reactions; First in man
  • Sponsors Roche

    • Most Recent Events

    • 30 Sep 2022 Status changed from active, no longer recruiting to completed.
    • 04 Mar 2022 Status changed from recruiting to active, no longer recruiting.
    • 01 Dec 2021 Planned End Date changed from 15 Sep 2023 to 15 Jan 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top